Sign up to save your podcasts
Or
Share Riyadh's AI Gambit: Pure Global on Cracking SFDA's New Digital Health Code.
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Riyadh's AI Gambit: Pure Global on Cracking SFDA's New Digital Health Code.
This week, we dive into a pivotal development in the MENA MedTech landscape: Saudi Arabia is aggressively defining its digital health future. The Saudi Food and Drug Authority (SFDA) is rolling out new workshops and enforcing its MDS-G27 guidance, creating a specific, and complex, regulatory pathway for AI and Software as a Medical Device (SaMD).
This episode unpacks what this means for international MedTech companies aiming to enter one of the largest markets in the Middle East. We move beyond the headlines to analyze the practical challenges and strategic opportunities this new focus presents, transforming a once-ambiguous process into a clearly defined, high-stakes entry point.
For example, a US-based startup with a groundbreaking AI diagnostic tool was previously stuck in regulatory limbo, unsure how to classify their software. Now, the new SFDA framework provides a clear path but demands rigorous new evidence on algorithm validation and cybersecurity, a challenge they are unprepared for. This is the critical gap where opportunity meets risk.
Key Questions from This Episode:
- What are the three most critical requirements within the SFDA's new MDS-G27 guidance for AI medical devices?
- How does the risk classification for SaMD in Saudi Arabia differ from EU or FDA standards?
- What specific cybersecurity vulnerabilities must be addressed in your submission?
- How can companies prepare a technical dossier that anticipates SFDA's questions on AI model validation?
- What does Saudi Arabia's move signal for the future of digital health regulation across the entire MENA region?
- Is your current global regulatory strategy compatible with this new digital-first approach?
At Pure Global, we specialize in demystifying these complexities. We offer end-to-end regulatory consulting solutions, leveraging local expertise and advanced AI tools to streamline your market access. Whether you're a startup or a multinational, we can help you navigate the evolving landscape in Saudi Arabia and over 30 other markets. Contact us at [email protected] or visit https://pureglobal.com/.
View all episodes
By Ran ChenThis week, we dive into a pivotal development in the MENA MedTech landscape: Saudi Arabia is aggressively defining its digital health future. The Saudi Food and Drug Authority (SFDA) is rolling out new workshops and enforcing its MDS-G27 guidance, creating a specific, and complex, regulatory pathway for AI and Software as a Medical Device (SaMD).
This episode unpacks what this means for international MedTech companies aiming to enter one of the largest markets in the Middle East. We move beyond the headlines to analyze the practical challenges and strategic opportunities this new focus presents, transforming a once-ambiguous process into a clearly defined, high-stakes entry point.
For example, a US-based startup with a groundbreaking AI diagnostic tool was previously stuck in regulatory limbo, unsure how to classify their software. Now, the new SFDA framework provides a clear path but demands rigorous new evidence on algorithm validation and cybersecurity, a challenge they are unprepared for. This is the critical gap where opportunity meets risk.
Key Questions from This Episode:
- What are the three most critical requirements within the SFDA's new MDS-G27 guidance for AI medical devices?
- How does the risk classification for SaMD in Saudi Arabia differ from EU or FDA standards?
- What specific cybersecurity vulnerabilities must be addressed in your submission?
- How can companies prepare a technical dossier that anticipates SFDA's questions on AI model validation?
- What does Saudi Arabia's move signal for the future of digital health regulation across the entire MENA region?
- Is your current global regulatory strategy compatible with this new digital-first approach?
At Pure Global, we specialize in demystifying these complexities. We offer end-to-end regulatory consulting solutions, leveraging local expertise and advanced AI tools to streamline your market access. Whether you're a startup or a multinational, we can help you navigate the evolving landscape in Saudi Arabia and over 30 other markets. Contact us at [email protected] or visit https://pureglobal.com/.